These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-001756-36 A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons... 2017-12-31 bad-data
Reported results 2004-002103-32 Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, el... 2014-01-16 due-trials
Ongoing, reported early 2004-004349-16 Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined wit... not-yet-due
Ongoing, reported early 2005-000734-21 A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma not-yet-due
Ongoing, reported early 2005-002344-26 GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLANTAT... not-yet-due
Ongoing 2005-005375-15 Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation not-yet-due
Ongoing, reported early 2006-000454-44 Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymp... not-yet-due
Ongoing 2006-004768-30 Traitement de première ligne des lymphomes du manteau de patients agés de 65 à 80 ans. Evaluation de l'efficacité, de la toxicité et de facteurs pronostiques moléculaires de l'inhibiteur du protéasome... not-yet-due
Ongoing 2006-007066-11 A phase II study evaluating the efficacy and safety of the farnesyltransferase inhibitor ZARNESTRA® (R115777, tipifarnib) in patients with relapsed , refractory or progressive mantle cell lymphoma not... not-yet-due
Reported results 2007-000270-23 TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WITH ... 2014-01-29 due-trials
Listed as ongoing, but also has a completion date 2007-000327-18 Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previousl... 2013-01-07 bad-data
Ongoing 2007-000699-18 Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of th... not-yet-due
Reported results 2007-001519-52 Randomized study of intensified CHOP plus Rituximab (R-CHOP given every 14 days: R-CHOP 14) versus CHOP plus Rituximab given every 21 days (R-CHOP 21) and randomized study of frontline-prophylatic Dar... 2012-04-06 due-trials
Reported results 2007-001589-34 Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma 2010-06-25 due-trials
Ongoing 2007-002414-19 Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chimio... not-yet-due
Not reported 2007-004644-70 Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âgés ... 2019-04-15 due-trials
Ongoing 2007-005580-95 An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follicula... not-yet-due
Ongoing 2007-007056-33 An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) mai... not-yet-due
Exempt, with results 2007-007698-22 A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA 2015-11-23 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-008202-52 DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE 2019-09-30 bad-data
Ongoing 2009-010017-72 Bendamustine in patients with refractory or relapsed T-cell lymphoma. A phase II multicenter study “BENTLY” not-yet-due
Not reported 2009-017279-77 Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 year... 2020-05-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-017995-26 PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA 2014-04-28 bad-data
Reported results 2010-020757-14 A multicentric phase II study evaluating the benefit of a short induction treatment by Bendamustine and Rituximab followed by maintenance therapy with rituximab In Elderly (≥ 60 years old) patients wi... 2016-07-01 due-trials
Reported results 2011-001356-10 STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)... 2019-03-21 due-trials
Ongoing 2011-002792-42 A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide ( CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously ... not-yet-due
Exempt, with results 2011-003849-18 A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM 18 ... 2016-03-22 not-yet-due
Exempt 2011-005150-62 A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. Etude de phase Ib/II de l’Obinutuz... not-yet-due
Ongoing 2011-005851-15 A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 OR RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATED P... not-yet-due
Listed as ongoing, but also has a completion date 2012-001580-68 Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with Previously Untreated Peripheral T-Cell Lymphoma. Ensayo clínico multic... 2016-05-10 bad-data
Ongoing 2012-002542-20 Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone... not-yet-due
Reported results 2012-004246-15 A Phase II study of oral JAK1/JAK2 inhibitor INC424 in adult patients with relapsed/refractory classical Hodgkin’s lymphoma 2018-06-12 due-trials
Ongoing 2013-000182-37 BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY not-yet-due
Listed as ongoing, but also has a completion date 2013-000450-22 Sub-cutaneous Rituximab-miniCHOP versus Sub-cutaneous Rituximab-miniCHOP + lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for patients of 80 years old or more. A multicentric phase III st... 2021-02-22 bad-data
Reported results 2013-000734-35 Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD Brentuximab vedotin en traitement de consolidation chez d... 2020-07-09 due-trials
Exempt, with results 2013-000771-33 BIBLOS (BTK Inhibition in B-cell LymphOmaS) BIBLOS (inhibition BTK dans les lymphomes à cellules B) not-yet-due
Ongoing 2014-000128-22 A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy) ... not-yet-due
Ongoing 2014-001002-17 A prospective phase II study of bendamustine in patients aged over 60 years with classical Hodgkin lymphoma treated by prednisone, vinblastine, and doxorubicin Etude prospective de phase II évaluan... not-yet-due
Exempt 2014-002722-13 Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation ... 2021-07-12 not-yet-due
Ongoing 2015-000929-37 EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy ... not-yet-due
Ongoing 2016-000548-33 Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven ma... not-yet-due
Exempt 2016-001499-31 A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP Etude de phase Ib-II du taze... not-yet-due
Exempt, with results 2016-003103-56 A phase Ib - II study of Entospletinib (ENTO) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with aaIPI ≥1 treated by R-CHOP 2019-10-18 not-yet-due
Ongoing 2016-005061-31 A PHASE II TRIAL EVALUATING COMBINATION OF ATEZOLIZUMAB, WITH VENETOCLAX AND OBINUTUZUMAB FOR RELAPSED/REFRACTORY LYMPHOMAS ETUDE DE PHASE II EVALUANT LA COMBINAISON ATEZOLIZUMAB, AVEC VENETOCLAX ... not-yet-due
Ongoing 2017-000409-19 A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance Etude de phase II du ... not-yet-due
Ongoing 2017-000719-17 A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposi... not-yet-due
Completed, report not yet due 2017-001939-38 A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions Etude de ph... 2021-08-12 not-yet-due
Other 2017-003909-17 Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell ... not-yet-due
Ongoing 2019-002105-22 A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma not-yet-due
Ongoing 2020-001985-12 A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy not-yet-due
Ongoing 2020-004910-37 A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma not-yet-due
Ongoing 2020-005225-81 A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA not-yet-due